IATDMCT has been fortunate to have experienced such generous levels of expert leadership and guidance. To this end we would like to acknowledge those who stepped forward and lead us to where we are today.
![]() |
IATDMCT PresidentYusuke Tanigawara |
Dr. Yusuke Tanigawara is Professor of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Tokyo, Japan. He teaches clinical pharmacology to medical students and post-graduate students. He is an Adjunct Faculty of University of Florida, College of Pharmacy.
He received his Ph. D. in pharmaceutical sciences from Kyoto University in 1983. He started working in the field of TDM since 1985 when he joined with Kyoto University Hospital as a faculty member responsible for TDM. His research interests include pharmacokinetics, pharmacodynamics and optimal dosing algorithms for personalized medicine. Oncology and infectious diseases are his major fields for research. He applied population pharmacokinetic and pharmacodynamic modeling to a number of new drug development as well as rational use of drugs for patient care such as clinical implementation of TDM. Recently, he also investigates multi-omics biomarkers including pharmacogenomics, proteomics and metabolomics as a novel indicator to predict responder/non-responder variation to drug therapy. He published more than 180 peer-reviewed original articles and 282 book chapters and review articles. He was distinguished as one of the “ISI Highly Cited Researchers” by Thomson Reuters ISI database.
He served as Secretary of the IATDMCT for 4 years, and Chair of the 15th Congress of IATDMCT in Kyoto, 2017. He was a past President of Japanese Society of Therapeutic Drug Monitoring (JSTDM).
![]() |
IATDMCT President-ElectDario Cattaneo |
Employment
Academic commitments
Education & Certification:
Professional Activities
Awards
Publications / scientific activities
Main clinical/research activities
Vision Statement
I envisage the future of the IATDMCT society as the key player for the tailoring of drug therapy in increasingly complicated patients (elderly, with comorbidities and heavy polypharmacy) at the bedside, taking advantage from the presence of active members with excellences and expertise in several fields. The accomplishment of this task requires, however, a day-by-day, two-way strict collaboration with specialists from different medical disciplines. In other words, the labs need to meet/match the clinics!
![]() |
IATDMCT SecretaryMaria Shipkova |
Employment
Education & Certification:
Professional Activities
Why would you be a good member of IATDMCT Council
As a longstanding member of IATDMCT for (>20 years) and somebody who had have the privilege to serve this Association at various positions over the past years I am glad to know many IATDMCT members and enjoy networking within IATDMCT. I hope that I have been able to convince with organizational-, communication-skills and persistence during my services and will be honored to continue my efforts for IATDMCT as a member of the Council.
![]() |
IATDMCT TreasurerDenise Anne McKeown |
Since September 2012, Denise has worked as a Forensic Toxicologist at Forensic Medicine and Science (FMS), University of Glasgow. Prior to this she worked for just under 10 years at Analytical Services International, St George’s - University of London under the supervision of IATDMCT Past-President Professor David W Holt. In both positions she has pursued her interest in bioanalytics; she specialises in the development and validation of hyphenated chromatographic and mass-spectrometric methods for the qualitative and quantitative detection of drugs, their metabolites and endogenous compounds for application in the areas of forensic and clinical toxicology. In her current position Denise is also a reporting Forensic Toxicologist and Expert Witness responsible for interpretation and communication of toxicological finding to the Scottish Courts.
For 12 years, Denise has been an active member of IATDMCT with a successful committee history. During a decade on the Young Scientists Committee as Vice-Chair then Chair, YS membership increased from 8 to 296 members. Denise was also the founding chair of the very active Communications Committee, who are integral to association activities. Denise looks forward to devoting the same enthusiasm to her role as IATDMCT Treasurer.
Employment:
Education & Certification:
Professional Activities:
![]() |
IATDMCT Past PresidentTeun van Gelder |
Dr. Teun van Gelder is an internist-nephrologist and clinical pharmacologist. He was trained in internal medicine and nephrology at the Erasmus Medical Center, and completed his thesis in 1996 on the use of anti-interleukin-2 receptor monoclonal antibodies in solid organ transplantation. As a post-doctoral scientist, he worked in the Transplantation Immunology Laboratory of Dr. Randall E. Morris at Stanford University (1998-2000), and was awarded the Young Investigator Award from the American Society for Transplantation for his work during this time.
Between 2000 and 2019 he worked in the Departments of Hospital Pharmacy and Internal Medicine at the Erasmus Medical Center in Rotterdam, the Netherlands. In 2010, at Erasmus Medical Center he was appointed Professor in Clinical Pharmacology. His research at the Erasmus Medical Center was focused on clinical pharmacology and therapeutic drug monitoring. He was the chairman of the Dutch Society for Clinical Pharmacology & Biopharmacy, the secretary of the Dutch Society for Transplantation, and the President of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology.
In December 2019 Teun van Gelder accepted a new position in Leiden University Medical Center (LUMC). He was appointed Professor in Drug Discovery & Development. LUMC, Leiden Institute of Chemistry, Leiden Academic Centre for Drug Research (LACDR), Centre for Human Drug Research (CHDR) and Leiden Bio Science Park (LBSP) together have the expertise and facilities for the design, development and testing of new innovative drugs. This environment is unique in the Netherlands, and provides an excellent basis for drug discovery and drug development. In his role as an experienced internist – clinical pharmacologist Teun will make an important contribution to Academic Pharma.
![]() |
Director of EducationDebbie Marriott |
Current Appointments
Certifications
Current Memberships - Professional Societies
Selection of Professional Activities (all to date unless otherwise indicated)
![]() |
Director of EducationMarkus Meyer |
Prof. Dr. Markus R. Meyer is a full Professor of Pharmacology & Toxicology at the Faculty of Medicine and at the Faculty of Pharmacy, Saarland University and head of the Department of Experimental and Clinical Toxicology at the Saarland University in Homburg, Germany. After he was promoted to PhD and gained his habilitation (venia legendi in pharmacology and toxicology) from the Saarland University, he moved to the Department of Clinical Pharmacology at the Karolinska Institutet in Stockholm, Sweden and thereafter to the Department of Clinical Pharmacology and Pharmacoepidemiology at Heidelberg University Hospital, Germany. His main area of research is analytical toxicology including in-vitro and in-vivo toxicokinetics.
He has published over 120 peer-reviewed original papers or review articles and received several international and national scientific awards amongst them the TIAFT Achievement Award and the GTFCh Young Scientist Award. Besides IATDMCT, Prof. Meyer is member of several international and national scientific societies such as the TIAFT, GTFCh, DGPT, and DGMS. He is currently IATDMCT board member and chair of the YS committee of the IATDMCT as well as vice chair of the TIAFT YS committee.
![]() |
Director of EducationStaffan Rosenborg |
Staffan Rosenborg graduated as an MD from Karolinska Institutet in 1996. He became a specialist in Nephrology in 2003 and in Clinical Pharmacology in 2007. Dr Rosenborg defended his PhD thesis “CYP2C dependent drug metabolism in vivo – influence of genetics and drug interactions” in 2010. Prof Teun van Gelder was the external examiner.
Dr Rosenborg was Head of Residents and Director of post-graduate training in Clinical Pharmacology at the Karolinska University Hospital between 2010 and 2013. From 2013 he has been the Head of the Clinical Pharmacology Trial Unit (CPTU) at the same hospital. The CPTU is a phase-I trial unit certified for first-in-human trials. Dr Rosenborg was awarded the Swedish Diploma in Clinical Trials in June 2016.
He is the secretary of the Swedish Foundation for Clinical Pharmacology and Pharmacotherapy and is also one of two Swedish representatives in the Section for Pharmacology of the Union Européenne des Médecines Spécialistes (UEMS). He has more than 500 lecturing hours, has organized courses in clinical pharmacokinetics and has participated in courses on leadership in postgraduate education.
Dr Rosenborg has some 20 peer reviewed publications in international journals and some 15 papers in Swedish journals. His areas of expertise include: different aspects of nephropharmacology (including drug dosing in dialysis), immunosuppressive drugs, pharmacokinetics, therapeutic drug monitoring, clinical trial design and conduct.
![]() |
IATDMCT CouncillorRyuji Kato |
Dr. Ryuji Kato is an Associate Professor of Cardiovascular Pharmacotherapy and Toxicology at Osaka University of Pharmaceutical Sciences, Osaka, Japan. He completed his master’s degree in 2000 at Osaka University and began his career as a pharmacist at the Yokkaichi Social Insurance Hospital (Mie, Japan). He then moved to Osaka University of Pharmaceutical Sciences as an Assistant Professor. In 2008, he received his PhD in Pharmaceutical Sciences.
His research interests primarily include the appropriate use of pharmaceutical products. He has conducted extensive research on pharmacokinetics, drug-drug interactions (chelation complexes, drug-drug interactions on cytochrome P450 or via transporters), and serious adverse side effects (QT prolongation, drug induced liver injury, interstitial pneumonia, Stevens-Johnson syndrome, and toxic epidermal necrolysis).
He is the author or co-author of approximately 70 peer-reviewed manuscripts. Dr. Kato is a member of the following academic societies: International Association of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT), Japanese Society of Therapeutic Drug Monitoring (JSTDM), Society of Toxicology (SOT), Pharmaceutical Society of Japan, and Japanese Society of Nephrology and Pharmacotherapy (JJNP). He has been a member of IATDMCT Communication Committee since 2015 and is an inspector for JSTDM.
![]() |
IATDMCT CouncillorChristophe Stove |
Christophe Stove, PharmD, PhD, is Associate Professor at the Department of Bioanalysis at Ghent University (Belgium). After a cell and molecular biology-oriented PhD and postdoc, he embarked upon bioanalysis in 2007 and became head of the Laboratory of Toxicology at the Faculty of Pharmaceutical Sciences in 2014. Besides teaching several courses, he directs the Lab’s service activities (forensic toxicology and reference lab activities (Ref4U)) and steers the research. The latter covers applied cell biology, as well as bioanalysis, with topics linked to the development of bio-assays as an alternative drug screening approach in forensic toxicology, to vitamer analysis, or to microsampling applications and associated challenges. He has over 125 publications, many of which in leading journals, and has an h-index of 28. He is active as a Board/Council Member of several national and international organizations (including TIAFT and IATDMCT).
![]() |
IATDMCT CouncillorNicolas Venisse |
Nicolas Venisse got his PharmD from the University of Bordeaux, France in 1999. He completed his PhD in Pharmaceutical Sciences at the University of Poitiers. He also received accreditation to supervise research from the University of Poitiers. He is expert at the court of appeal of Poitiers.
He currently works at the Toxicology and Pharmacokinetics department at the University Hospital of Poitiers. He is also a member of the HEDEX (Health - Endocrine Disruptors – Exposome) research group at the Clinical Investigation Center of Poitiers (CIC INSERM 1402).
He is a member of several professional organizations including : Société Française de Pharmacologie et Thérapeutique and IATDMCT. He is the current chair of the Toxicology and Environmental Health scientific committee at IATDMCT. He is a member of the French National Academy of Pharmacy (Académie Nationale de Pharmacie), Environmental Health Committee (6éme section, Santé Environnementale).
He has over 40 peer-reviewed publications and 10 book chapters. His areas of expertise include: environmental toxicology, pharmaco- and toxico-kinetics, bioanalysis and PK/TK modeling.
![]() |
IATDMCT CouncillorMiao Yan |
Employment
Education & Certification
Professional Activities
![]() |
IATDMCT PresidentTeun van Gelder |
Teun van Gelder is a Professor in Clinical Pharmacology, as well as an internist-nephrologist and clinical pharmacologist in the Department of Hospital Pharmacy and Department of Internal Medicine at the Erasmus Medical Center in Rotterdam, the Netherlands.
Professor van Gelder was trained in internal medicine and nephrology at the Erasmus Medical Center, and completed his thesis in 1996 on the use of anti-interleukin-2 receptor monoclonal antibodies in solid organ transplantation. As a postdoctoral scientist, he worked in the Transplantation Immunology Laboratory of Dr Randall E Morris at Stanford University (1998-2000), and was awarded the Young Investigator Award from the American Society for Transplantation for his work during that time.
Professor van Gelder’s current research at the Erasmus Medical Center is focused on clinical pharmacology and therapeutic drug monitoring. He is the chairman of the Dutch Society for Clinical Pharmacology and president-elect of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology.
![]() |
IATDMCT Past PresidentLoralie Langman |
Loralie Langman got her BSc in Laboratory Medicine and Pathology, CSMLS, and ASCP certifications at the University of Alberta. She completed her Ph.D. Laboratory Medicine and Pathology at the University of Alberta. She completed her Clinical Chemistry training at the University of Toronto, specializing in Forensic Toxicology and Molecular Genetics. She worked in Vancouver, British Columbia, at the Provincial Toxicology Centre and BC Biomedical Laboratories as a Forensic Toxicologist/Clinical Chemist. She is currently the Director, Toxicology and Drug Monitoring Laboratory, Mayo Clinic Rochester, MN and Associate Professor of Laboratory Med/Pathology, Mayo Clinic College of Medicine.
Dr. Langman was certified with the Canadian Academy of Clinical Biochemistry (CACB) and is the first individual to have achieved Diplomat status with the American Board of Clinical Chemistry (ABCC) in all three disciplines (Clinical Chemistry, Molecular Diagnostics, Toxicological Chemistry). She is also a Diplomat with the American Board of Forensic Toxicology.
Dr. Langman is a member of and serves on committees for several professional organizations including: The Society of Forensic Toxicologists (SOFT); the American Academy of Forensic Sciences (AAFS); the National Academy of Clinical Biochemistry (NACB); the Canadian Society of Clinical Chemists (CSCC); The International Association of Forensic Toxicologists (TIAFT), the American Association for Clinical Chemistry (AACC), the International Federation of Clinical Chemistry And Laboratory Medicine (IFCC) and IATDMCT.
She has over 47 peer reviewed publications, 12 book chapters, over 60 abstracts and over 100 presentations at National and International meetings. Her areas of expertise include: clinical toxicology; drugs of abuse (particularly amphetamine-type stimulants and cocaine); post-mortem toxicology; therapeutic drug management (particularly immunosuppressant drugs); and pharmacogenetics.
![]() |
IATDMCT President-ElectYusuke Tanigawara |
Dr. Yusuke Tanigawara is Professor of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Tokyo, Japan. He teaches clinical pharmacology to medical students and post-graduate students. He is an Adjunct Faculty of University of Florida, College of Pharmacy.
He received his Ph. D. in pharmaceutical sciences from Kyoto University in 1983. He started working in the field of TDM since 1985 when he joined with Kyoto University Hospital as a faculty member responsible for TDM. His research interests include pharmacokinetics, pharmacodynamics and optimal dosing algorithms for personalized medicine. Oncology and infectious diseases are his major fields for research. He applied population pharmacokinetic and pharmacodynamic modeling to a number of new drug development as well as rational use of drugs for patient care such as clinical implementation of TDM. Recently, he also investigates multi-omics biomarkers including pharmacogenomics, proteomics and metabolomics as a novel indicator to predict responder/non-responder variation to drug therapy. He published more than 180 peer-reviewed original articles and 282 book chapters and review articles. He was distinguished as one of the “ISI Highly Cited Researchers” by Thomson Reuters ISI database.
He served as Secretary of the IATDMCT for 4 years, and Chair of the 15th Congress of IATDMCT in Kyoto, 2017. He was a past President of Japanese Society of Therapeutic Drug Monitoring (JSTDM).
![]() |
IATDMCT SecretaryMaria Shipkova |
Dr. med. Maria Shipkova received her medical education at the Medical University, Sofia, Bulgaria, where she specialized in Laboratory Medicine. In 1992 she joined the TDM laboratory headed by Prof. Dobrin Svinarov, Chair for Clinical Laboratory, Sofia. In 1995 Dr. Shipkova was awarded a Tempus Phare postdoctoral fellowship from the European Union to broaden her education in therapeutic drug monitoring at the Department of Clinical Chemistry, Georg-August-University, Göttingen, under its Director, Prof Michael Oellerich. At the conclusion of this appointment she remained in Göttingen as a resident and was involved in a variety of routine and research activities in the field of transplantation and immunosuppressive drug monitoring. In 2003 Dr. Shipkova moved to Stuttgart, where she now pursues her work in the field of the therapeutic drug monitoring as a Senior Scientist at the institute of Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart. She is responsible for the therapeutic drug monitoring/toxjcology section.
In 2005 Maria Shipkova was awarded with the Young Investigator Award of the International Society for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT). Her research interests are focused on drug metabolism & drug toxicity, development & evaluation of analytical methods, and most recently biomarkers as a tool to optimize immunosuppressive therapy.
Dr. Shipkova has authored over 100 peer- reviewed publications and has supervised several doctoral theses and post-doc fellows in the field of the therapeutic drug monitoring. She was the Chair of the IATDMCT immunosuppressive Drugs Scientific Committee (2013-2015) and IATDMCT Director of Education (2015 – 2017). Dr Shipkova is currently Vice-Chair of the Communications Committee of the IATDMCT. She has held the following positions: Coordinator "TDM of Everolimus" Consensus Project (2013-2016), Member of the IATDMCT Biomarkers in transplantation Working Group (2009 -), Associated member of the Bulgarian Academy of Science and Arts, past Editor in Chief of the IATDMCT Newsletter "Compass" (2009 - 2015).
![]() |
IATDMCT TreasurerDenise Anne McKeown |
Since September 2012, Denise has worked as a Forensic Toxicologist at Forensic Medicine and Science (FMS), University of Glasgow. Prior to this she worked for just under 10 years at Analytical Services International, St George’s - University of London under the supervision of IATDMCT Past-President Professor David W Holt. In both positions she has pursued her interest in bioanalytics; she specialises in the development and validation of hyphenated chromatographic and mass-spectrometric methods for the qualitative and quantitative detection of drugs, their metabolites and endogenous compounds for application in the areas of forensic and clinical toxicology. In her current position Denise is also a reporting Forensic Toxicologist and Expert Witness responsible for interpretation and communication of toxicological finding to the Scottish Courts.
For 12 years, Denise has been an active member of IATDMCT with a successful committee history. During a decade on the Young Scientists Committee as Vice-Chair then Chair, YS membership increased from 8 to 296 members. Denise was also the founding chair of the very active Communications Committee, who are integral to association activities. Denise looks forward to devoting the same enthusiasm to her role as IATDMCT Treasurer.
Employment:
Education & Certification:
Professional Activities:
![]() |
Director of EducationKatharina Rentsch |
Katharina M. Rentsch studied pharmacy at the ETH in Zurich, Switzerland and obtained the pharmacist's license in 1988. Thereafter she got a certification as specialist for laboratory medicine FAMH for clinical chemistry and clinical immunology in 1991. In 1996 she finished her PhD thesis on TDM of cytostatic drugs at the ETH Zurich. In 2003 she finished her habilitation in the field of clinical chemistry at the department of chemistry and applied biosciences of the ETH Zurich and in 2007 she habilitated at the medical faculty of the University Zurich, Switzerland. In 2010 she became an adjunct professor at the medical faculty of the University Zurich and in 2012 at the medical faculty of the University Basel. In 2007 she certified as a clinical toxicologist GTFCh.
From 1994 to 2011 Dr Rentsch has been the head of the laboratory for drug analysis and clinical toxicology at the Institute for Clinical Chemistry, University Hospital Zurich. Since December 2011 she is the head of the division of clinical chemistry at the University Hospital Basel, Switzerland. Since May 2014 head of the laboratory medicine at the University Hospital Basel, Switzerland.
Her main research interest is the development of new analytical methodologies for TDM and CT, and their application in different clinical studies as well as the implementation of TDM procedures for new drugs. She is author or co-author of over 150 peer-reviewed publications, 8 book chapters and over 60 published oral or poster presentations.
Dr Rentsch is a member of and serves on committees for several professional organizations including: Swiss Society of Clinical Chemistry (SSCC), the International Association of Forensic Toxicology (TIAFT), the American Association for Clinical Chemistry (AACC), the German Society of Toxicological and Forensic Chemistry (GTFCh) and IATDMCT. Since 2006 she is member of the IATDMCT Clinical Toxicology/Drugs of Abuse Committee and has been a member of the scientific board of the Basel Meeting in 2003 and of the local organizing meeting of the Stuttgart Meeting in 2011.
![]() |
Director of EducationErik van Maarseveen |
Dr. Erik van Maarseveen got his Pharmacy Degree in 2005 and started his career as a pharmacist at the Gouda Hospital (The Netherlands). That same year he obtained the Certificate of Fundamentals of Business & Economics for Beta’s as part of the Master program “Business and Economics for Beta’s” at Utrecht University. His 4-year-training as a hospital pharmacist commenced in 2006 at Central Hospital Pharmacy, The Hague and the Gouda Hospital. Dr. van Maarseveen has been working as a registered hospital pharmacist since 2010 at the University Medical Center Utrecht (The Netherlands), where he leads the therapeutic drug monitoring and toxicology laboratory which is equipped with GC, HPLC, UPLC, LC-MSMS and Orbitrap-LCMS techniques.
Dr. van Maarseveen and his team develop bio-analytical assays primarily for therapeutic drug monitoring and clinical toxicology purposes with the ultimate goal to improve treatment outcomes. Directly after he obtained his PhD on optimizing treatment of once daily dosed aminoglycosides and continuously infused vancomycin, he embarked on his clinical pharmacologist training, which he completed in 2016. Currently, his research focusses on clinical pharmacology and clinical mass spectrometry in solid organ and stem cell transplantation, infectious diseases, cystic fibrosis and oncology. Among others, he is co-applicant of a grant of the Dutch KiKa (Children Cancerfree) foundation awarded to investigate the pharmacology of conditioning agents in stem cell transplantation conditioning. Van Maarseveen is a member of the TDM in Oncology scientific committee of the IATDMCT association, chair of the special interest group on Transplantation and member of the committee on Analysis & Toxicology of the Dutch Association for Hospital Pharmacists. In 2016, he was installed as a board member of the Dutch Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology.
Furthermore, Dr van Maarseveen, who is in possession of a University Teaching Qualification, teaches pharmacology, TDM and toxicology to both pharmacy and medical students at Utrecht University. Dr van Maarseveen has published over 35 peer-reviewed papers (https://www.researchgate.net/profile/Erik_Van_Maarseveen2) and acts as a reviewer for several clinical and pharmacology journals. In 2015 he was granted the award for best publication by the Dutch Association for Hospital Pharmacists.
![]() |
Director of EducationStaffan Rosenborg |
Staffan Rosenborg graduated as an MD from Karolinska Institutet in 1996. He became a specialist in Nephrology in 2003 and in Clinical Pharmacology in 2007. Dr Rosenborg defended his PhD thesis “CYP2C dependent drug metabolism in vivo – influence of genetics and drug interactions” in 2010. Prof Teun van Gelder was the external examiner.
Dr Rosenborg was Head of Residents and Director of post-graduate training in Clinical Pharmacology at the Karolinska University Hospital between 2010 and 2013. From 2013 he has been the Head of the Clinical Pharmacology Trial Unit (CPTU) at the same hospital. The CPTU is a phase-I trial unit certified for first-in-human trials. Dr Rosenborg was awarded the Swedish Diploma in Clinical Trials in June 2016.
He is the secretary of the Swedish Foundation for Clinical Pharmacology and Pharmacotherapy and is also one of two Swedish representatives in the Section for Pharmacology of the Union Européenne des Médecines Spécialistes (UEMS). He has more than 500 lecturing hours, has organized courses in clinical pharmacokinetics and has participated in courses on leadership in postgraduate education.
Dr Rosenborg has some 20 peer reviewed publications in international journals and some 15 papers in Swedish journals. His areas of expertise include: different aspects of nephropharmacology (including drug dosing in dialysis), immunosuppressive drugs, pharmacokinetics, therapeutic drug monitoring, clinical trial design and conduct.
![]() |
IATDMCT CouncillorDebbie Marriott |
Current Appointments
Certifications
Current Memberships - Professional Societies
Selection of Professional Activities (all to date unless otherwise indicated)
![]() |
IATDMCT CouncillorMarkus Meyer |
Prof. Dr. Markus R. Meyer is a full Professor of Pharmacology & Toxicology at the Faculty of Medicine and at the Faculty of Pharmacy, Saarland University and head of the Department of Experimental and Clinical Toxicology at the Saarland University in Homburg, Germany. After he was promoted to PhD and gained his habilitation (venia legendi in pharmacology and toxicology) from the Saarland University, he moved to the Department of Clinical Pharmacology at the Karolinska Institutet in Stockholm, Sweden and thereafter to the Department of Clinical Pharmacology and Pharmacoepidemiology at Heidelberg University Hospital, Germany. His main area of research is analytical toxicology including in-vitro and in-vivo toxicokinetics.
He has published over 120 peer-reviewed original papers or review articles and received several international and national scientific awards amongst them the TIAFT Achievement Award and the GTFCh Young Scientist Award. Besides IATDMCT, Prof. Meyer is member of several international and national scientific societies such as the TIAFT, GTFCh, DGPT, and DGMS. He is currently IATDMCT board member and chair of the YS committee of the IATDMCT as well as vice chair of the TIAFT YS committee.
![]() |
IATDMCT CouncillorMichael Neely |
Dr. Neely’s research and clinical interests are in pediatric clinical pharmacometrics, including population pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, biomarker control, simulation, and most importantly, use of models to optimize therapy for individual patients. He is a practicing pediatric infectious diseases specialist. Although Dr. Neely primarily works in the therapeutic area of infectious diseases on anti-infective compounds, he has experience with other therapeutic areas.
Michael Neely is the Acting Chief of Infectious Diseases and Director of the Laboratory of Applied Pharmacokinetics and Bioinformatics (LAPKB) at the Children's Hospital of Los Angeles and an Associate Professor of Pediatrics and Clinical Scholar at the University of Southern California (USC) Keck School of Medicine. He created Pmetrics, a non-parametric and parametric population modeling and simulation package for R based on over four decades of work by members of LAPKB. He also created an R package for LAPKB’s BestDose software to optimize drug therapy for individual patients. He works with multidisciplinary faculty collaborators in the USC Departments of Pediatrics, Medicine, and Preventive Medicine, as well as in the School of Pharmacy.
Dr. Neely has a Master’s of Science in Clinical and Biomedical Investigations from USC, with a focus on applied Bayesian approaches to clinical trial design and pharmacokinetic modeling. He was a member of the United States Food and Drug Administration Anti-infective Drug Advisory Committee and now periodically consults for the committee. He is a Regent of the American College of Clinical Pharmacology, a founding member of the International Society of Pharmacometrics, and an active member of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. He has been the PI on an NIH K23 training grant, two R01s, and is co-PI of a third R01, as well as co-investigator on numerous other NIH grants, with continuous NIH funding since 2007.
Michael Neely has published more than 100 peer-reviewed articles, mentored numerous visiting scholars, and is an invited speaker worldwide.
![]() |
IATDMCT CouncillorChristophe Stove |
Employment
Education & Certification:
Professional Activities:
Activities specifically related to IATDMCT
Teaching activities
Responsible for the following courses at Ghent University:
Research Activities (general):
Service Activities (external):
![]() |
IATDMCT PresidentLoralie Langman |
Loralie Langman got her BSc in Laboratory Medicine and Pathology, CSMLS, and ASCP certifications at the University of Alberta. She completed her Ph.D. Laboratory Medicine and Pathology at the University of Alberta. She completed her Clinical Chemistry training at the University of Toronto, specializing in Forensic Toxicology and Molecular Genetics. She worked in Vancouver, British Columbia, at the Provincial Toxicology Centre and BC Biomedical Laboratories as a Forensic Toxicologist/Clinical Chemist. She is currently the Director, Toxicology and Drug Monitoring Laboratory, Mayo Clinic Rochester, MN and Associate Professor of Laboratory Med/Pathology, Mayo Clinic College of Medicine.
Dr. Langman was certified with the Canadian Academy of Clinical Biochemistry (CACB) and is the first individual to have achieved Diplomat status with the American Board of Clinical Chemistry (ABCC) in all three disciplines (Clinical Chemistry, Molecular Diagnostics, Toxicological Chemistry). She is also a Diplomat with the American Board of Forensic Toxicology.
Dr. Langman is a member of and serves on committees for several professional organizations including: The Society of Forensic Toxicologists (SOFT); the American Academy of Forensic Sciences (AAFS); the National Academy of Clinical Biochemistry (NACB); the Canadian Society of Clinical Chemists (CSCC); The International Association of Forensic Toxicologists (TIAFT), the American Association for Clinical Chemistry (AACC), the International Federation of Clinical Chemistry And Laboratory Medicine (IFCC) and IATDMCT.
She has over 47 peer reviewed publications, 12 book chapters, over 60 abstracts and over 100 presentations at National and International meetings. Her areas of expertise include: clinical toxicology; drugs of abuse (particularly amphetamine-type stimulants and cocaine); post-mortem toxicology; therapeutic drug management (particularly immunosuppressant drugs); and pharmacogenetics.
![]() |
IATDMCT Past PresidentPierre Wallemacq |
Dr Pierre Wallemacq, is Professor at the Université Catholique de Louvain, Medical school in Brussels, Belgium. He teaches clinical chemistry, toxicology and clinical pharmacokinetics, and is the vice president of the Biomedical Sciences School. He is one of the co-founders of the Louvain centre for Toxicology and Applied Pharmacology (LTAP) in the Medical School, and supervises several PhD theses and post-doc fellows. He is also head of Clinical Chemistry Department in the Cliniques universitaires St Luc, Brussels, in charge of the automated CoreLab platform as well as of the analytical biochemistry platform regrouping specific activities such as TDM, clinical toxicology, forensic toxicology, but also special chemistry and endocrinology (GC, HPLC, UPLC, LC-MSMS, GC-MS).
He started working in the field of TDM since 1982 with his PhD thesis on cyclosporine, and is author or co-author of more than 180 peer-reviewed manuscripts and nine textbook chapters. He has presented at more than 200 conferences on invitation. Most of his work was dedicated to immunosuppressive drugs, but he also published works in other clinical chemistry or TDM/TOX areas. Pierre Wallemacq is the past-president of the Royal Belgian Society of Clinical Chemistry (SRBCC-KBVKC), and is the current president of the Belgian and Luxemburg society of Toxicology (BLT). He is member of the Editorial Boards of several International Journals such as Therapeutic Drug Monitoring (TDM), Clinical Biochemistry (CLB), Clinical Chemistry and Laboratory Medicine (CCLM). Since July 2009, he serves as Associate Editor for Clinical Biochemistry. He received the IATDMCT C.E. Pippenger award in 2011 for outstanding contribution to Therapeutic drug Monitoring, and was nominated member of the Royal Belgian Academy of Medicine (ARMB) in 2012.
![]() |
IATDMCT President-ElectTeun van Gelder |
Employment
Education & Certification
Professional Activities
Web-of-Science: 346 publications, H-index 39, with 6079 citations (as of March 2015)
Speaker at numerous conferences, both national and international.
Awards
Vision Statement
Therapeutic drug monitoring and analysis+consulting for clinical toxicology are forms of personalized medicine “avant la lettre”. IATDMCT has promoted the individualization of treatment before the term personalized medicine had even been invented. Our strength is the analytical expertise and translation of laboratory results into practical treatment recommendations . My mission will be to promote the added value of our contribution, to increase the visibility of IATDMCT and to increase involvement of clinicians into our Association.
![]() |
IATDMCT SecretaryYusuke Tanigawara |
Professor Yusuke Tanigawara is Professor of Clinical Pharmacokinetics and Pharmacodynamics, School of Medicine, Keio University, Tokyo, Japan. He received his Ph. D. in pharmaceutical sciences from Kyoto University in 1983. His research interests include pharmacokinetics, pharmacodynamics and optimal dosing algorithms for personalized medicine. He has been studying clinical pharmacokinetics and pharmacodynamics mainly in oncology and infectious diseases. His modeling and simulation studies on population pharmacokinetics and pharmacodynamics were applied to new drug development as well as rational use for routine patient care. He also investigates multi-omics biomarkers such as genomics, proteomics and metabolomics as factors causing individual variation in drug response. He is distinguished as one of the "ISI Highly Cited Researchers."
Employment
Education & Certification
Professional Activities
Other academic and professional appointments:
Vision Statement
As the current Secretary, I have been working hard to expand the IATDMCT network worldwide. During last 2 years, the Association has significantly grown due to the increased number of members particularly in Asian region. I am pleased to make efforts to contribute to the IATDMCT as Secretary.
![]() |
IATDMCT TreasurerGwendolyn McMillin |
Gwendolyn A. McMillin received a BA from Grinnell College, in Grinnell, IA, and a PhD in pharmacology and toxicology from the University of Utah, in Salt Lake City, UT. She completed post-doctoral training in Clinical Chemistry through the University of Utah, and is certified by the American Board of Clinical Chemistry (ABCC) in the areas of Clinical Chemistry and Toxicological Chemistry. She is currently an Associate Professor (clinical) of Pathology at the University of Utah, and is a Medical Director at ARUP Laboratories, responsible for the areas of Clinical Toxicology and Pharmacogenomics.
Dr McMillin is actively involved in professional associations. For example, she served as Chair of the TDM/Toxicology Division of the American Association for Clinical Chemistry (AACC), Chair of the Toxicological Chemistry exam and Continuing Education Committee for the American Board of Clinical Chemistry (ABCC), a Member of the Toxicology Resource Committee for the College of American Pathologists (CAP), and is co-Chair of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology's (IATDMCT) 2013 Congress. She was also involved in forming the Personalized Medicine Division of the AACC. Dr McMillin serves as an Editorial Board member for professional journals such as Therapeutic Drug Monitoring and the Journal of Analytical Toxicology, and has published nearly 100 original research manuscripts, review articles, and book chapters. Her research is focused on evaluating and assuring clinical utility of drug testing and pharmacogenomics, funded by several commercial contracts and federal grants.
Employment
Education & Certification
Professional Activities
Activities in IATDMCT:
Activities in AACC (American Association for Clinical Chemistry):
Activities in CAP (College of American Pathologists):
Activities in ABCC (American Board of Clinical Chemistry):
Editorial Board Member: Therapeutic Drug Monitoring; Journal of Analytical Toxicology
Active publication record:
I have authored/published in excess of 70 original manuscripts; 10 review articles; 25 book chapters; and 150 abstracts
My experience as IATDMCT Treasurer since 2013 has prepared me to serve on the Council. I am organized and successful in completing projects in a timely manner, and I am both excited and privileged to have opportunity to continue serving the organization by managing the finances for another term.
![]() |
Director of EducationMercè Brunet |
Mercè Brunet is Professor of Pharmacology and Toxicology at the University of Barcelona; Medical School of Barcelona. She is currently the Head of Pharmacology and Toxicology in the Biologic Diagnostic Center of the Hospital Clínic of Barcelona. She got her Ph.D. in Pharmaceutical Sciences from Barcelona University in 1980.
Mercè Brunet's main research interests are focus on treatment personalization, mainly concerning the measurement of biomarkers that may reflect immunosuppressive drugs’ exposure and effect, using pharmacokinetic, pharmacogenetic and pharmacodynamic approaches. Recently most of her work is dedicated to new pharmacokinetic/ pharmacodynamics monitoring strategies for antitumor drugs. She has published over 105 original articles in peer-reviewed international journals and 9 book chapters.
Employment
Education & Certification
Professional Activities
IATDMCT Awards
Activities in IATDMCT
Other Awards
Other Professional / Educational Activities (2010-2015)
Publications
![]() |
Director of EducationKatharina Rentsch |
Katharina M. Rentsch studied pharmacy at the ETH in Zurich, Switzerland and obtained the pharmacist's license in 1988. Thereafter she got a certification as specialist for laboratory medicine FAMH for clinical chemistry and clinical immunology in 1991. In 1996 she finished her PhD thesis on TDM of cytostatic drugs at the ETH Zurich. In 2003 she finished her habilitation in the field of clinical chemistry at the department of chemistry and applied biosciences of the ETH Zurich and in 2007 she habilitated at the medical faculty of the University Zurich, Switzerland. In 2010 she became an adjunct professor at the medical faculty of the University Zurich and in 2012 at the medical faculty of the University Basel. In 2007 she certified as a clinical toxicologist GTFCh.
From 1994 to 2011 Dr Rentsch has been the head of the laboratory for drug analysis and clinical toxicology at the Institute for Clinical Chemistry, University Hospital Zurich. Since December 2011 she is the head of the division of clinical chemistry at the University Hospital Basel, Switzerland.
Her main research interest is the development of new analytical methodologies for TDM and CT, and their application in different clinical studies as well as the implementation of TDM procedures for new drugs. She is author or co-author of 100 peer-reviewed publications, 8 book chapters and 50 published oral or poster presentations.
Dr Rentsch is currently the head of the Swiss Society of Clinical Chemistry and she is a member of the IATDMCT, the International Association of Forensic Toxicology (TIAFT), the American Association for Clinical Chemistry (AACC), the German Society of Toxicological and Forensic Chemistry (GTFCh), and several other local professional organizations. Since 2006 she is member of the IATDMCT Clinical Toxicology/Drugs of Abuse Committee and has been a member of the scientific board of the Basel Meeting in 2003 and of the local organizing meeting of the Stuttgart Meeting in 2011.
Employment
Education & Certification
Professional Activities
Memberships and Activities in Scientific Societies
Executive and committee positions held
Activities for IATDMCT
Number of Publications
Professional Appointments
![]() |
Director of EducationMaria Shipkova |
Employment
Education & Certification
Academic Degrees
Professional Registrations
Professional Activities
Professional Society Memberships
Publications
93 articles contributed to scientific journals on the following topics: therapeutic drug monitoring, drug metabolism, drug toxicity, development and evaluation of analytical methods, organ function tests, biomarkers of drug effects.
Stipends and Awards
Varia
![]() |
IATDMCT CouncillorDebbie Marriott |
Current Appointments
Certifications
Current Memberships - Professional Societies
Selection of Professional Activities (all to date unless otherwise indicated)
![]() |
IATDMCT CouncillorMarkus Meyer |
Employment
Education & Certification
Professional Activities
![]() |
IATDMCT CouncillorFranck Saint-Marcoux |
Dr Franck Saint-Marcoux is President of the TDM group of the French Society of Pharmacology and Therapeutics (SFPT) and Chair of the IATDMCT Pharmacometrics Committee. He is currently responsible for the Pharmacology and Pharmacokinetic Unit of the Pharmacology and Toxicology department of the Limoges University Hospital (France), and is a member of the INSERM research unit "Pharmacology of the immunosuppressive drugs in transplantation" directed by Prof. Pierre Marquet.
Dr Franck Saint-Marcoux obtained a Master of Advanced Studies in Pharmacy and a PhD in Pharmacokinetic Modelling in 2004. His research activity is focused on the development of PK tools useful for routine activity of TDM, mainly immunosuppressants, but also antibiotics or anticancer drugs. He is author or co-author of over 40 papers in peer-reviewed international journals.
Employment
Franck Saint-Marcoux is currently:
Education & Certification
Franck Saint-Marcoux is PharmD, PhD
Professional Activities
![]() |
IATDMCT CouncillorChristoph Seger |
Christoph Seger studied Chemistry and Biochemistry at the University of Vienna, Austria (PhD 2001, University of Vienna). After focusing on NMR based structure elucidation of Natural Products and peptides (Max Planck Institute for Biochemistry, Martinsried, Germany) for several years he took up a lecturer position at the Institute of Pharmacy at the University of Graz, Austria, followed by Post-Doc appointment at the Institute of Pharmacy at the University of Innsbruck, Austria. He obtained his venia legendi (Habilitation) at the University of Innsbruck in 2008 for his research focus on Pharmaceutical Analysis.
Since 2005 he is technical head of the ISO 15189 accredited Mass Spectrometry and Chromatography laboratory at the Central Institute of Medicinal and Chemical Laboratory Diagnostics (ZIMCL) / University Hospital Innsbruck, Austria which focuses on TDM and endocrinology testing.
Besides serving as council member for the IATDMCT, where he is also ISD scientific committee member, he is a board member of the Austrian Society for Analytical Chemistry (ASAC) and the Austrian Society of Laboratory Medicine and Clinical Chemistry (ÖGLMKC). He serves as review team I / II member for the Joint Committee for Traceability in Laboratory Medicine (JCTLM) Working Group and has been appointed as PT scheme leader for drugs of the Austrian Society for Quality Assurance and Standardization of Medical-Diagnostics (ÖQUASTA).
He is involved in academic teaching at the University of Innsbruck, the Medical University Innsbruck and the UMIT. In addition he has supervised more than a dozen BA, MS, and PhD theses projects. His publication record currently holds 60+ peer reviewed papers and reviews, about 50 conference abstracts in peer reviewed journals, 40 invited lectures and more than 130 other conference contributions (lectures, poster presentations).
![]() |
IATDMCT PresidentPierre Wallemacq |
Dr Pierre Wallemacq, is Professor at the Université Catholique de Louvain, Medical school in Brussels, Belgium. He teaches clinical chemistry, toxicology and clinical pharmacokinetics, and is the vice president of the Biomedical Sciences School. He is one of the co-founders of the Louvain centre for Toxicology and Applied Pharmacology (LTAP) in the Medical School, and supervises several PhD theses and post-doc fellows. He is also head of Clinical Chemistry Department in the Cliniques universitaires St Luc, Brussels, in charge of the automated CoreLab platform as well as of the analytical biochemistry platform regrouping specific activities such as TDM, clinical toxicology, forensic toxicology, but also special chemistry and endocrinology (GC, HPLC, UPLC, LC-MSMS, GC-MS).
He started working in the field of TDM since 1982 with his PhD thesis on cyclosporine, and is author or co-author of more than 180 peer-reviewed manuscripts and nine textbook chapters. He has presented at more than 200 conferences on invitation. Most of his work was dedicated to immunosuppressive drugs, but he also published works in other clinical chemistry or TDM/TOX areas. Pierre Wallemacq is the past-president of the Royal Belgian Society of Clinical Chemistry (SRBCC-KBVKC), and is the current president of the Belgian and Luxemburg society of Toxicology (BLT). He is member of the Editorial Boards of several International Journals such as Therapeutic Drug Monitoring (TDM), Clinical Biochemistry (CLB), Clinical Chemistry and Laboratory Medicine (CCLM). Since July 2009, he serves as Associate Editor for Clinical Biochemistry. He received the IATDMCT C.E. Pippenger award in 2011 for outstanding contribution to Therapeutic drug Monitoring, and was nominated member of the Royal Belgian Academy of Medicine (ARMB) in 2012.
![]() |
IATDMCT President-ElectLoralie Langman |
Loralie Langman got her BSc in Laboratory Medicine and Pathology, CSMLS, and ASCP certifications at the University of Alberta. She completed her Ph.D. Laboratory Medicine and Pathology at the University of Alberta. She completed her Clinical Chemistry training at the University of Toronto, specializing in Forensic Toxicology and Molecular Genetics. She worked in Vancouver, British Columbia, at the Provincial Toxicology Centre and BC Biomedical Laboratories as a Forensic Toxicologist/Clinical Chemist. She is currently the Director, Toxicology and Drug Monitoring Laboratory, Mayo Clinic Rochester, MN and Associate Professor of Laboratory Med/Pathology, Mayo Clinic College of Medicine.
Dr. Langman was certified with the Canadian Academy of Clinical Biochemistry (CACB) and is the first individual to have achieved Diplomat status with the American Board of Clinical Chemistry (ABCC) in all three disciplines (Clinical Chemistry, Molecular Diagnostics, Toxicological Chemistry). She is also a Diplomat with the American Board of Forensic Toxicology.
Dr. Langman is a member of and serves on committees for several professional organizations including: The Society of Forensic Toxicologists (SOFT); the American Academy of Forensic Sciences (AAFS); the National Academy of Clinical Biochemistry (NACB); the Canadian Society of Clinical Chemists (CSCC); The International Association of Forensic Toxicologists (TIAFT), the American Association for Clinical Chemistry (AACC), the International Federation of Clinical Chemistry And Laboratory Medicine (IFCC) and IATDMCT.
She has over 47 peer reviewed publications, 12 book chapters, over 60 abstracts and over 100 presentations at National and International meetings. Her areas of expertise include: clinical toxicology; drugs of abuse (particularly amphetamine-type stimulants and cocaine); post-mortem toxicology; therapeutic drug management (particularly immunosuppressant drugs); and pharmacogenetics.
![]() |
IATDMCT Past PresidentPierre Marquet |
Pierre Marquet has been a Doctor of Medicine since 1986 and obtained a master in statistics and epidemiology followed by a PhD in physiology in 1992. After several years as an assistant professor at Limoges University Hospital, he became an associate professor of pharmacology in 1998 and since 2001, has been a full professor at the Faculty of Medicine of Limoges, France. He was presented with the Young Scientist Award of the French Society of Analytical Toxicology in 1995, the IATDMCT Young Investigator Award in 2001 and C.E. Pippenger Award in 2009. At the IATDMCT, he chaired the Standard of Laboratory Practice Committee from 2001-2007, was elected Secretary in 2007 and then President-elect in 2009.
Pierre Marquet is currently:
Pierre Marquet conducts translational research on treatment personalization, mainly concerning immunosuppressants (IS) in organ transplantation, which covers: new analytical methodologies for IS; metabolic, pharmacogenetic and pharmacodynamic studies of the IS; investigation of early biomarkers; epidemiological studies and clinical trials in transplant patients; and application to routine treatment personalization in transplant recipients. He has published over 160 papers in peer-reviewed, international journals. He is the coordinator of the European research program "Biomarkers of Renal Graft Injuries" (BIOMARGIN, FP7 Health).
![]() |
IATDMCT SecretaryYusuke Tanigawara |
Professor Yusuke Tanigawara is Professor of Clinical Pharmacokinetics and Pharmacodynamics, School of Medicine, Keio University, Tokyo, Japan. He received his Ph. D. in pharmaceutical sciences from Kyoto University in 1983. His research interests include pharmacokinetics, pharmacodynamics and optimal dosing algorithms for personalized medicine. He has been studying clinical pharmacokinetics and pharmacodynamics mainly in oncology and infectious diseases. His modeling and simulation studies on population pharmacokinetics and pharmacodynamics were applied to new drug development as well as rational use for routine patient care. He also investigates multi-omics biomarkers such as genomics, proteomics and metabolomics as factors causing individual variation in drug response. He is distinguished as one of the "ISI Highly Cited Researchers."
![]() |
IATDMCT TreasurerGwendolyn McMillin |
Gwendolyn A. McMillin received a BA from Grinnell College, in Grinnell, IA, and a PhD in pharmacology and toxicology from the University of Utah, in Salt Lake City, UT. She completed post-doctoral training in Clinical Chemistry through the University of Utah, and is certified by the American Board of Clinical Chemistry (ABCC) in the areas of Clinical Chemistry and Toxicological Chemistry. She is currently an Associate Professor (clinical) of Pathology at the University of Utah, and is a Medical Director at ARUP Laboratories, responsible for the areas of Clinical Toxicology and Pharmacogenomics.
Dr McMillin is actively involved in professional associations. For example, she served as Chair of the TDM/Toxicology Division of the American Association for Clinical Chemistry (AACC), Chair of the Toxicological Chemistry exam and Continuing Education Committee for the American Board of Clinical Chemistry (ABCC), a Member of the Toxicology Resource Committee for the College of American Pathologists (CAP), and is co-Chair of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology's (IATDMCT) 2013 Congress. She was also involved in forming the Personalized Medicine Division of the AACC. Dr McMillin serves as an Editorial Board member for professional journals such as Therapeutic Drug Monitoring and the Journal of Analytical Toxicology, and has published nearly 100 original research manuscripts, review articles, and book chapters. Her research is focused on evaluating and assuring clinical utility of drug testing and pharmacogenomics, funded by several commercial contracts and federal grants.
![]() |
Director of EducationMercè Brunet |
Mercè Brunet is Professor of Pharmacology and Toxicology at the University of Barcelona; Medical School of Barcelona. She is currently the Head of Pharmacology and Toxicology in the Biologic Diagnostic Center of the Hospital Clínic of Barcelona. She got her Ph.D. in Pharmaceutical Sciences from Barcelona University in 1980.
Mercè Brunet is also currently:
Mercè Brunet's main research interests are focus on treatment personalization, mainly concerning the measurement of biomarkers that may reflect immunosuppressive drugs’ exposure and effect, using pharmacokinetic, pharmacogenetic and pharmacodynamic approaches. Recently most of her work is dedicated to new pharmacokinetic/ pharmacodynamics monitoring strategies for antitumor drugs. She has published over 105 original articles in peer-reviewed international journals and 9 book chapters.
![]() |
Director of EducationVanessa Steenkamp |
Professor Vanessa Steenkamp obtained her PhD in Clinical Chemistry (Toxicology of traditional herbal remedies). Presently she heads the Phytomedicine Unit, Department of Pharmacology, University of Pretoria, South Africa. She is Past-President of the South African Association of Clinical Biochemistry, Vice-President of the Toxicology Society of South Africa and Secretary-General of the South African Association of Basic & Clinical Pharmacology. Internationally she serves as vice-chair of the IATDMCT Clinical Toxicology committee and participates in the Standards of Laboratory Practice committee. She is a member of the nominating committee of the International Union of Toxicology and serves on the Executive Committee of the IFCC. She strives to better health care provision and with her dedication to the African Federation of Clinical Chemistry, regional federation of the IFCC, of which she is currently President, was inaugurated in 2009.
Vanessa is author/co-author of >70 scientific papers and 3 book chapters. Awards for her research both nationally & internationally, amongst others, include: the prestigious Friedel Sellschop award and Exceptional Young Researcher of the University of Pretoria, the Young Scientist Award from the IATDMCT and AACC. Reviewer for 18 international peer-reviewed journals and on the editorial board of 4 journals. She has lectured worldwide and in 2010 was awarded the IATDMCT travelling lectureship where she presented toxicology lectures in Chile. Vanessa is registered with the Health Professions Council of South Africa as a medical scientist, the South African Council for Natural Scientific Professions (SACNSP) as a Professional Natural Scientist and is a rated scientist with the National Research Foundation. She serves on the Professional Advisory Committee of SACNSP. At the University she serves on various academic and research committees. She has supervised 28 post graduate students to graduation and 10 currently under her supervision.
![]() |
Director of EducationEberhard Wieland |
Eberhard Wieland is Professor of Clinical Chemistry and Laboratory Medicine . He is Medical Director and head of the Central Institute for Clinical Chemistry and Laboratory Medicine, Klinikum Stuttgart, Germany.
Dr. Wieland received his MD in Biochemistry from the Ruprecht-Karls-University, Heidelberg in 1982. Between 1983 and 1985 he was resident in Internal Medicine and received a training in Medical Microbiology at the University Hospital, Heidelberg.
In 1985 he was awarded a research fellowship by the Volkswagen foundation which he spent between 1985 and 1987 at the Department of Endocrinology and Metabolism of the University of California, San Diego, USA.
From 1987 to 1993 he received his training in Clinical Chemistry and Laboratory Medicine at the Georg-August-University Goettingen. In 1993 he was certified in Clinical Chemistry and became consultant in Laboratory Medicine. In 2000 he was appointed Professor of Clinical Chemistry.
Dr. Wieland became Medical Director and head of the Central Institute of Clinical Chemistry and Laboratory Medicine of Klinikum Stuttgart in 2003. He is teaching Clinical Chemistry and Laboratory Medicine at the Eberhard-Karls-University in Tuebingen.
Dr. Wieland conducts research in pharmacokinetics and pharamacodynamics of immunosupressant drugs. His current research interest is in biomarkers to complement TDM. In addition, he performs funded research on oxidative stress in transplantation medicine and atherosclerosis. Dr. Wieland has contributed over 90 articles for peer reviewed scientific journals and 16 book chapters on the topics TDM, atherosclerosis, oxidative stress and biomarkers. He has presented more than 160 lectures and posters at national and international events. He is an editorial board member of Clinical Biochemistry, Canada; Folia Medica Plovid, Bulgaria; and Journal of Laboratory Medicine, Germany. He is also an active referee for German accreditation bodies.
![]() |
IATDMCT CouncillorOlof Beck |
Olof Beck studied chemistry at the Royal Institute of Technology in Stockholm and received his Ph.D. degree in 1982 after working at the Karolinska Institute with studies on biogenic amines using gas chromatography-mass spectrometry methods. After a post-doctoral period at Stanford University and two years in pharmaceutical industry he returned to Karolinska Institute and department of Clinical Pharmacology in 1988. Dr. Beck is at present adjunct professor and laboratory director of the Pharmacology Laboratory comprising TDM, genotyping, clinical and workplace drugs-of-abuse testing, sports doping control and contract analyses in clinical trials. He has been active assessor in laboratory accreditation in the Nordic countries.
Research activities have resulted in about 200 publications. Areas of interest are method developments in pharmacology and toxicology with special focus on mass spectrometry, alcohol biomarkers and toxicology. Most recent work is focused on Internet drugs, breath testing for abused drugs and alcohol biomarker phosphatidylethanol.
![]() |
IATDMCT CouncillorKatharina Rentsch |
Katharina M. Rentsch studied pharmacy at the ETH in Zurich, Switzerland and obtained the pharmacist's license in 1988. Thereafter she got a certification as specialist for laboratory medicine FAMH for clinical chemistry and clinical immunology in 1991. In 1996 she finished her PhD thesis on TDM of cytostatic drugs at the ETH Zurich. In 2003 she finished her habilitation in the field of clinical chemistry at the department of chemistry and applied biosciences of the ETH Zurich and in 2007 she habilitated at the medical faculty of the University Zurich, Switzerland. In 2010 she became an adjunct professor at the medical faculty of the University Zurich and in 2012 at the medical faculty of the University Basel. In 2007 she certified as a clinical toxicologist GTFCh.
From 1994 to 2011 Dr Rentsch has been the head of the laboratory for drug analysis and clinical toxicology at the Institute for Clinical Chemistry, University Hospital Zurich. Since December 2011 she is the head of the division of clinical chemistry at the University Hospital Basel, Switzerland.
Her main research interest is the development of new analytical methodologies for TDM and CT, and their application in different clinical studies as well as the implementation of TDM procedures for new drugs. She is author or co-author of 100 peer-reviewed publications, 8 book chapters and 50 published oral or poster presentations.
Dr Rentsch is currently the head of the Swiss Society of Clinical Chemistry and she is a member of the IATDMCT, the International Association of Forensic Toxicology (TIAFT), the American Association for Clinical Chemistry (AACC), the German Society of Toxicological and Forensic Chemistry (GTFCh), and several other local professional organizations. Since 2006 she is member of the IATDMCT Clinical Toxicology/Drugs of Abuse Committee and has been a member of the scientific board of the Basel Meeting in 2003 and of the local organizing meeting of the Stuttgart Meeting in 2011.
![]() |
IATDMCT CouncillorFranck Saint-Marcoux |
Dr Franck Saint-Marcoux is President of the TDM group of the French Society of Pharmacology and Therapeutics (SFPT) and Chair of the IATDMCT Pharmacometrics Committee. He is currently responsible for the Pharmacology and Pharmacokinetic Unit of the Pharmacology and Toxicology department of the Limoges University Hospital (France), and is a member of the INSERM research unit "Pharmacology of the immunosuppressive drugs in transplantation" directed by Prof. Pierre Marquet.
Dr Franck Saint-Marcoux obtained a Master of Advanced Studies in Pharmacy and a PhD in Pharmacokinetic Modelling in 2004. His research activity is focused on the development of PK tools useful for routine activity of TDM, mainly immunosuppressants, but also antibiotics or anticancer drugs. He is author or co-author of over 40 papers in peer-reviewed international journals.
![]() |
IATDMCT CouncillorChristoph Seger |
Christoph Seger studied Chemistry and Biochemistry at the University of Vienna, Austria (PhD 2001, University of Vienna). After focusing on NMR based structure elucidation of Natural Products and peptides (Max Planck Institute for Biochemistry, Martinsried, Germany) for several years he took up a lecturer position at the Institute of Pharmacy at the University of Graz, Austria, followed by Post-Doc appointment at the Institute of Pharmacy at the University of Innsbruck, Austria. He obtained his venia legendi (Habilitation) at the University of Innsbruck in 2008 for his research focus on Pharmaceutical Analysis.
Since 2005 he is technical head of the ISO 15189 accredited Mass Spectrometry and Chromatography laboratory at the Central Institute of Medicinal and Chemical Laboratory Diagnostics (ZIMCL) / University Hospital Innsbruck, Austria which focuses on TDM and endocrinology testing.
Besides serving as council member for the IATDMCT, where he is also ISD scientific committee member, he is a board member of the Austrian Society for Analytical Chemistry (ASAC) and the Austrian Society of Laboratory Medicine and Clinical Chemistry (ÖGLMKC). He serves as review team I / II member for the Joint Committee for Traceability in Laboratory Medicine (JCTLM) Working Group and has been appointed as PT scheme leader for drugs of the Austrian Society for Quality Assurance and Standardization of Medical-Diagnostics (ÖQUASTA).
He is involved in academic teaching at the University of Innsbruck, the Medical University Innsbruck and the UMIT. In addition he has supervised more than a dozen BA, MS, and PhD theses projects. His publication record currently holds 60+ peer reviewed papers and reviews, about 50 conference abstracts in peer reviewed journals, 40 invited lectures and more than 130 other conference contributions (lectures, poster presentations).
Position | Name | Organization Location |
President | Pierre Marquet | University Hospital Limoges Limoges, France |
President-Elect | Pierre Wallemacq | University Hospital St. Luc Brussels, Belgium |
Past President | Alexander (Sander) A. Vinks | Cincinnati Children's Hospital and Medical Center Cincinnati, OH, USA |
Secretary | Donald LeGatt | University of Alberta Hospital Edmonton, AB, Canada |
Treasurer | Loralie J. Langman | Mayo Clinic Rochester, MN, USA |
Director of Education | Tuen van Gelder | Erasmus Medical Center Rotterdam, The Netherlands |
Director of Education | Paul Taylor | Princess Alexandra Hospital Brisbane, QLD, Australia |
Director of Education | Eberhard Wieland | Klinikum Stuttgart Stuttgart, Germany |
Councilor | Olof Beck | Karolinska Institutet Stockholm, Sweden |
Councilor | Frank T. Peters | University Hospital Jena Jena, Germany |
Councilor | Katharina Rentsch | University Hospital Basel Basel, Switzerland |
Councilor | Benedetta Sallustio | The Queen Elizabeth Hospital Woodville, SA, Australia |
Position | Name | Organization Location |
President | Alexander (Sander) A. Vinks | Cincinnati Children's Hospital and Medical Center Cincinnati, OH, USA |
President-Elect | Pierre Marquet | University Hospital Limoges Limoges, France |
Past President | Hans H. Maurer | Saarland University Homburg/Saar, Germany |
Secretary | Donald LeGatt | University of Alberta Hospital Edmonton, AB, Canada |
Treasurer | Loralie J. Langman | Mayo Clinic Rochester, MN, USA |
Director of Education | Tuen van Gelder | Erasmus Medical Center Rotterdam, The Netherlands |
Director of Education | Vanessa Steenkamp | University of Pretoria Pretoria, South Africa |
Director of Education | Pierre Wallemacq | University Hospital St. Luc Brussels, Belgium |
Councilor | Mercè Brunet | Hospital Clinic of Barcelona Barcelona, Spain |
Councilor | William Clarke | Johns Hopkins Medicine Baltimore, MD, USA |
Councilor | Frank T. Peters | Friedrich Schiller University of Jena Jena, Germany |
Councilor | Benedetta Sallustio | The Queen Elizabeth Hospital Woodville, SA, Australia |
Position | Name | Organization Location |
President | Hans H. Maurer | Saarland University Homburg, Germany |
President-Elect | Alexander (Sander) A. Vinks | Cincinnati Children's Hospital and Medical Center Cincinnati, OH, USA |
Past President | David W. Holt | St. George's University of London London, UK |
Secretary | Pierre Marquet | University Hospital Limoges Limoges, France |
Treasurer | Victor W. Armstrong | Georg-August-Universität Göttingen Göttingen, Germany |
Director of Education | Marilyn Huestis | Biomedical Research Center (NIDA/NIH) Baltimore, MD, USA |
Director of Education | Atholl Johnston | Barts / London Queen Mary's University London, UK |
Director of Education | Sandra Solari | Catholic University of Chile Santiago, Chile |
Councilor | Christine Collier | Kingston General Hospital / Queen's University Kingston, ON, Canada |
Councilor | Loralie J. Langman | Mayo Clinic Rochester, MN, USA |
Councilor | Tuen van Gelder | Erasmus Medical Center Rotterdam, The Netherlands |
Councilor | Pierre Wallemacq | University Hospital St. Luc Brussels, Belgium |
Position | Name | Organization Location |
President | David W. Holt | St. George's University of London London, UK |
President-Elect | Hans H. Maurer | University of Saarland Homburg , Germany |
Past President | Steven J. Soldin | Children's National Medical Center / George Washington University Washington, DC, USA |
Secretary | Alexander (Sander) A. Vinks | Cincinnati Children's Hopital and Medical Center Cincinnati, OH, USA |
Treasurer | Victor W. Armstrong | Georg-August-Universität Göttingen Göttingen, Germany |
Director of Education | Uwe Christians | University of Colorado Health Sciences Center Denver, CO, USA |
Director of Education | Atholl Johnston | Barts / London Queen Mary's University London, UK |
Director of Education | Sandra Solari | Catholic University of Chile Santiago, Chile |
Councilor | Christine Collier | Kingston General Hospital / Queen's University Kingston, ON, Canada |
Councilor | Claire George | City Hospital Birmingham W. Midlands, UK |
Councilor | Paul J. Taylor | Princess Alexandra Hospital Brisbane, QLD, Australia |
Councilor | Li Wang | Peking University First Hospital Beijing, China |
Position | Name | Organization Location |
President | Steven J. Soldin | Children's National Medical Center / George Washington University Washington, DC, USA |
President-Elect | David W. Holt | St. George's University of London London, UK |
Past President | Albert D. Fraser | Queen Elizabeth II Health Sciences Centre / Capital Health Halifax, NS, Canada |
Secretary | Alexander (Sander) A. Vinks | Cincinnati Children's Hopital and Medical Center Cincinnati, OH, USA |
Treasurer | Raymond G. Morris | The Queen Elizabeth Hospital Woodville, SA, Australia |
Director of Education | Uwe Christians | University of Colorado Health Sciences Center Denver, CO, USA |
Director of Education | Donald LeGatt | University of Alberta Hospitals Edmonton, AB, Canada |
Director of Education | Hans H. Maurer | University of Saarland Homburg, Germany |
Councilor | Victor W. Armstrong | Georg-August-Universität Göttingen Göttingen, Germany |
Councilor | Paul J. Taylor | Princess Alexandra Hospital Brisbane, QLD, Australia |
Councilor | Li Wang | Peking University First Hospital Beijing, China |
Councilor | John F. Wilson | Wales College of Medicine Cardiff, Wales, UK |
Position | Name | Organization Location |
President | Albert D. Fraser | Queen Elizabeth II Health Sciences Centre Halifax, NS, Canada |
President-Elect | Steven J. Soldin | Children's National Medical Center / George Washington University Washington, DC, USA |
Past President | Leslie (Les) M. Shaw | Hospital of the University of Pennsylvania Philadelphia, PA, USA |
Secretary | Kimberly L. Napoli | University of Texas Medical School at Houston Houston, TX, USA |
Treasurer | Raymond G. Morris | The Queen Elizabeth Hospital Woodville, SA, Australia |
Director of Education | Donald LeGatt | University of Alberta Hospitals Edmonton, AB, Canada |
Director of Education | Hans H. Maurer | University of Saarland Homburg, Germany |
Director of Education | Susan Tett | The University of Queensland Brisbane, QLD, Australia |
Councilor | Victor W. Armstrong | Georg-August-Universität Göttingen Göttingen, Germany |
Councilor | Leendert J. Mostert | Deltalab Poortugaal, The Netherlands |
Councilor | Michael Stewart | University of the Witwatersrand Medical School Parktown, South Africa |
Councilor | John F. Wilson | University of Wales Cardiff, Wales, UK |
Position | Name | Organization Location |
President | Leslie (Les) M. Shaw | Hospital of the University of Pennsylvania Philadelphia, PA, USA |
President-Elect | Albert D. Fraser | Queen Elizabeth II Health Sciences Centre Halifax, NS, Canada |
Past President | Michael Oellerich | Georg-August-Universität Göttingen Göttingen, Germany |
Secretary | Kimberly L. Napoli | University of Texas Medical School at Houston Houston, TX, USA |
Treasurer | Tai C. Kwong | University of Rochester Medical Center Rochester, NY, USA |
Director of Education | David W. Holt | St. George's Hospital Medical School London, UK |
Director of Education | Raymond G. Morris | The Queen Elizabeth Hospital Woodville, SA, Australia |
Director of Education | Alexander (Sander) A. Vinks | The University of Cincinnati College of Medicine Cincinatti, OH, USA |
Councilor | Ken Ilett | University of Western Australia Nedlands, WA, Australia |
Councilor | Donald LeGatt | University of Alberta Hospitals Edmonton, AB, Canada |
Councilor | Michael Stewart | University of the Witwatersrand Medical School Parktown, South Africa |
Councilor | Alison Thomson | University of Glasgow / Western Infirmary Glasgow, Scotland, UK |
Position | Name | Organization Location |
President | Michael Oellerich | Georg-August-Universität Göttingen Göttingen, Germany |
President-Elect | Leslie (Les) M. Shaw | Hospital of the University of Pennsylvania Philadelphia, PA, USA |
Past President | Philip Walson | Children's Hospital Medical Center Cincinnati, OH, USA |
Secretary | Albert D. Fraser | Queen Elizabeth II Health Sciences Centre Halifax, NS, Canada |
Treasurer | Tai C. Kwong | University of Rochester Medical Center Rochester, NY, USA |
Director of Education | Victor W. Armstrong | Georg-August-Universität Göttingen Göttingen, Germany |
Director of Education | David W. Holt | St. George's Hospital Medical School London, UK |
Director of Education | Kimberly L. Napoli | University of Texas Medical School Houston, TX, USA |
Councilor | Raymond G. Morris | The Queen Elizabeth Hospital Woodville, SA, Australia |
Councilor | Philip N. Patsalos | UCL Institute of Neurology London, UK |
Councilor | Dobrin A. Svinarov | Medical University of Sofia Sofia, Bulgaria |
Councilor | Steven H.Y. Wong | Medical College of Wisconsin Milwaukee, WI, USA |
Position | Name | Organization Location |
President | Philip Walson | University of Cincinnati Children's Hospital Medical Center Cincinnati, OH, USA |
President-Elect | Michael Oellerich | Georg-August-Universität Göttingen Göttingen, Germany |
Past President | Ian D. Watson | University Hospital Aintree Liverpool, UK |
Secretary | Albert D. Fraser | Queen Elizabeth II Health Sciences Centre Halifax, NS, Canada |
Treasurer | Leslie (Les) M. Shaw | Hospital of the University of Pennsylvania Philadelphia, PA, USA |
Director of Education | Julia Potter | Royal Brisbane Hospital Herston, QLD, Australia |
Director of Education | Juliette Säwe | Karolinska Institute / Huddinge University Hospital Huddinge, Sweden |
Director of Education | Steven H.Y. Wong | Medical College of Wisconsin Milwaukee, WI, USA |
Councilor | David W. Holt | St. George's Hospital Medical School London, UK |
Councilor | Takashi Mimaki | Gifu University Gifu City, Japan |
Councilor | Raymond G. Morris | The Queen Elizabeth Hospital Woodville, SA, Australia |
Councilor | Kimberly L. Napoli | University of Texas Medical School Houston, TX, USA |
Position | Name | Organization Location |
President | Ian D. Watson | University Hospital Aintree Liverpool, UK |
President-Elect | Philip Walson | University of Cincinnati Children's Hospital Medical Center Cincinnati, OH, USA |
Past President | Steven H.Y. Wong | Medical College of Wisconsin Milwaukee, WI, USA |
Secretary | Randall Yatscoff | Isotechnika Inc. Edmonton, AB, Canada |
Treasurer | Roger Boeckx | Abbott Laboratories Libertyville, IL, USA |
Director of Education | Petrie Rainey | Yale School of Medicine New Haven, CT, USA |
Director of Education | Leslie (Les) M. Shaw | Hospital of the University of Pennsylvania Philadelphia, PA, USA |
Director of Education | Folke Sjӧqvist | Karolinska Institutet / Huddinge University Hospital Huddinge, Sweden |
Councilor | Halina Matsumoto | The Medical University School of Warsaw Warsaw, Poland |
Councilor | Julia Potter | Royal Brisbane Hospital Herston, QLD, Australia |
Councilor | Kazuhiko Tanaka | Osaka University of Pharmaceutical Sciences Osaka, Japan |
Councilor | Ester Zylber-Katz | Hadassah University Hospital Jerusalem, Israel |
Position | Name | Organization Location |
President | Steven H.Y. Wong | Medical College of Wisconsin Milwaukee, WI, USA |
President-Elect | Ian D. Watson | University Hospital Aintree Liverpool, UK |
Past President | n/a | |
Secretary | Philip Walson | University of Cincinnati Children's Hospital Medical Center Cincinnati, OH, USA |
Treasurer | Roger Boeckx | Abbott Laboratories Libertyville, IL, USA |
Director of Education | Petrie Rainey | Yale School of Medicine New Haven, CT, USA |
Director of Education | Folke Sjӧqvist | Karolinska Institutet / Huddinge University Hospital Huddinge, Sweden |
Director of Education | n/a | |
Councilor | Anthony Fell | |
Councilor | Halina Matsumoto | The Medical University School of Warsaw Warsaw, Poland |
Councilor | John Miners | Flinders Medical Center Bedford Park, SA, Australia |
Councilor | Kazuhiko Tanaka | Osaka University of Pharmaceutical Sciences Osaka, Japan |